Today, the benefits of GLP-1 receptor agonists also encompass mitigation of risk for Major adverse cardiovascular events (MACE), myocardial infarction, stroke, cardiovascular death, peripheral artery disease, and heart failure.5 This evidence concerns the gene GLP1R and heart failure.